MapLight Therapeutics, Inc.
MPLT
$28.50
-$0.77-2.63%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -42.31% | 325.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.64% | 164.71% | |||
| Operating Income | 22.64% | -164.71% | |||
| Income Before Tax | 23.73% | -170.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.73% | -170.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.73% | -170.41% | |||
| EBIT | 22.64% | -164.71% | |||
| EBITDA | 22.70% | -165.41% | |||
| EPS Basic | 45.85% | 93.35% | |||
| Normalized Basic EPS | 46.10% | 93.23% | |||
| EPS Diluted | 45.85% | 93.35% | |||
| Normalized Diluted EPS | 46.10% | 93.23% | |||
| Average Basic Shares Outstanding | 40.83% | 3,963.84% | |||
| Average Diluted Shares Outstanding | 40.83% | 3,963.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||